Review
Open access
Sep 2026
[In vivo CAR-T cells: When the patient becomes their own factory].
The main delivery platforms under clinical investigation are described, focusing on lentiviral vectors and lipid nanoparticles, and their differences in terms of mechanisms of action, associated risks, and optimization strategies are discussed.
François Vilcot, Carole-Anne Brugère, Jaime Fuentealba et al.
· Bulletin du Cancer · 0 citations